Eli Lilly And Company last reported quarterly results on Oct 29, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $24.4 billion (+38.6% year over year) and diluted EPS of $7.22. It usually reports 29–36 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 3, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Feb 4, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 29–36 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 29, 2026
29 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
24,397
+38.6%
|
6,451
+15.5%
|
7.22
+16.3%
|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
22,974
+47.7%
|
7,095
+25.3%
|
7.94
+26.2%
|
|
Apr 30, 2026
30 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
19,799
+55.5%
|
7,396
+168.1%
|
8.26
+169.9%
|
|
Feb 4, 2026
35 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
19,292
+42.6%
|
6,638
+50.5%
|
7.39
+51.4%
|
|
Oct 30, 2025
30 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
17,601
+53.9%
|
5,583
+475.4%
|
6.21
+480.4%
|
|
Aug 7, 2025
38 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
15,558
+37.6%
|
5,661
+90.8%
|
6.29
+91.8%
|
|
May 1, 2025
31 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
12,729
+45.2%
|
2,759
+23.0%
|
3.06
+23.4%
|
|
Jan 14, 2025
14 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
13,533
+44.7%
|
4,410
+101.4%
|
4.88
+101.6%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LLY (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- IN
- Headquarters
- Indianapolis, IN
- SEC filer status
- Large accelerated filer
- SEC CIK
- 59478
- Former names
- LILLY ELI & CO (until Oct 25, 2019); LILLY ELI & CO ET AL (until Oct 14, 1994)
Other Pharmaceutical Preparations companies
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
- Pfizer Inc PFE
Source: SEC EDGAR filings. This is company-reported data, not investment advice.